Creative Planning

Creative Planning’s Alexion Pharmaceuticals ALXN Stock Holding History

Creative Planning’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-900	Closed	-$8K	–	2158
2019 Q4	$8K	Hold	900	–	–	﹤0.01%	1925
2019 Q3	$2K	Hold	900	–	–	﹤0.01%	1961
2019 Q2	$28K	Buy	+900	New	+$116K	﹤0.01%	1865

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Creative Planning's ALXN Position: Q3 2021 in Review

Creative Planning sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,931 shares — an estimated $355K sold.

Creative Planning first reported a position in ALXN in Q2 2013 and held it in 32 quarters. The position peaked at $3.32M in Q4 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Creative Planning reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Creative Planning sold 1,931 Alexion Pharmaceuticals shares in Q3 2021, an estimated $355K.
Creative Planning first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 32 quarters.
Creative Planning's Alexion Pharmaceuticals position peaked at $3.32M in Q4 2017.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Creative Planning's 13F filing for Q3 2021, filed 10 Nov 2021.